Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;9(7):1090-1094.
doi: 10.1002/acn3.51595. Epub 2022 May 19.

Remyelination in humans due to a retinoid-X receptor agonist is age-dependent

Christopher E McMurran  1 , Trisha Mukherjee  1 , J William L Brown  1   2   3 , Andrew W Michell  1 , Declan T Chard  2   4 , Robin J M Franklin  1   5 , Alasdair J Coles  1 , Nick G Cunniffe  1
Affiliations

Remyelination in humans due to a retinoid-X receptor agonist is age-dependent

Christopher E McMurran et al. Ann Clin Transl Neurol. 2022 Jul.

Abstract

Remyelination efficiency declines with advancing age in animal models, but this has been harder to demonstrate in people with multiple sclerosis. We show that bexarotene, a putatively remyelinating retinoid-X receptor agonist, shortened the visual evoked potential latency in patients with chronic optic neuropathy aged under 42 years only (with the effect diminishing by 0.45 ms per year of age); and increased the magnetization transfer ratio of deep gray matter lesions in those under 43 years only. Addressing this age-related decline in human remyelination capacity will be an important step in the development of remyelinating therapies that work across the lifespan.

PubMed Disclaimer

Conflict of interest statement

CEM, TM, AWM, AJC, and NGC report no conflict of interest. JWLB reports personal fees from Biogen for real‐world evidence consultation, outside the submitted work. DTC is a consultant for Biogen and Hoffmann‐La Roche. In the last 3 years he has received research funding from Hoffmann‐La Roche, the International Progressive MS Alliance, the MS Society, and the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre, and speaker's honorarium from Novartis. He co‐supervises a clinical fellowship at the National Hospital for Neurology and Neurosurgery, London, which is supported by Merck. RJMF reports consulting fees from Frequency Therapeutics, Rewind Therapeutics and Biogen.

Figures

Figure 1
Figure 1
(A) Variation of P100 latency reduction (improvement) with patient age for eyes with a prolonged baseline latency (>118 m). Each data point represents an eye, and the model fit with 95% confidence interval is shown. (B) Treatment effect (bexarotene vs. placebo) from (A) as a function of age. The region to the left of the dashed line shows the age range at which there is a significant treatment effect with type 1 error rate (α) = 0.05. [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 2
Figure 2
(A) Variation of lesion MTR increase (improvement) with patient age for the three regions with statistically significant increases in MTR. The bexarotene group is shown in blue and placebo in red. Each data point represents a lesion, with superimposed horizontal jitter to better visualize lesions with the same patient age. The model fit with 95% confidence interval is shown. (B) Volcano plot showing the effect of age on lesion MTR improvement within the bexarotene group for the locations plotted in (A). Other brain regions are shown in gray for comparison. (C) Treatment effect (bexarotene vs. placebo) for deep gray matter lesions as a function of age. The region to the left of the dashed line shows the age range at which there is a significant treatment effect with type 1 error rate (α) = 0.05. GM = gray matter, MTR = magnetization transfer ratio. [Colour figure can be viewed at wileyonlinelibrary.com]
See this image and copyright information in PMC

Comment in

References

    1. Neumann B, Baror R, Zhao C, et al. Metformin restores CNS remyelination capacity by rejuvenating aged stem cells. Cell Stem Cell. 2019;25:473‐485.e8. - PMC - PubMed
    1. Segel M, Neumann B, Hill MFE, et al. Niche stiffness underlies the ageing of central nervous system progenitor cells. Nature. 2019;573:130‐134. - PMC - PubMed
    1. Ruckh JM, Zhao J‐W, Shadrach JL, et al. Rejuvenation of regeneration in the aging central nervous system. Cell Stem Cell. 2012;10:96‐103. - PMC - PubMed
    1. Neumann B, Segel M, Chalut KJ, Franklin RJM. Remyelination and ageing: reversing the ravages of time. Mult Scler J. 2019;25:1835‐1841. - PMC - PubMed
    1. Cadavid D, Balcer L, Galetta S, et al. Predictors of response to opicinumab in acute optic neuritis. Ann Clin Transl Neurol. 2018;5:1154‐1162. - PMC - PubMed

MeSH terms